The system includes the fully magnetically suspended BrioVAD Pump and uniquely engineered external components. Credit: BrioHealth Solutions / Business Wire.

BrioHealth Solutions has commenced subject enrolment in the US for the randomised INNOVATE trial, which will assess the BrioVAD system in treating refractory left ventricular heart failure.

The controlled, prospective, non-blinded, non-inferiority, multi-centre trial aims to assess the effectiveness and safety of the system.  

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

It is set to determine if patients living with the system spend less time in the hospital compared to those with the standard of care left ventricular assist device (LVAD).

Featuring the fully magnetically suspended BrioVAD Pump, the BrioVAD System is a full-support, durable ventricular assist device designed to enhance the quality of life in patients.

It also includes uniquely engineered external components and has been under development since 2008.

More than 350 non-Americans were treated with ventricular assist systems incorporating the ‘BrioVAD Pump technology’.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The pump’s magnetic bearing design allows for a smaller pump size with a larger impeller, decreasing surgical invasiveness.

Additionally, the BrioVAD Pump’s driveline design, which electrically connects the pump to external components, results in a thinner and more flexible driveline. This feature may potentially lessen driveline-associated infections.

The external patient-worn components of the system have been structured to improve user experience with only two components, potentially improving patient quality of life.

The BrioVAD Pump’s construction and large diameter impeller combination facilitate an improved blood flow pathway design within the pump. This design is expected to improve device hemocompatibility and hemodynamics, thereby reducing the critical complication risk.

BrioHealth Solutions CEO Chen Chen said: “We are thrilled to kick off the INNOVATE trial, following a phenomenal journey of innovation, engineering, and quality refinement to bring the BrioVAD System to life.

“Despite advancements in ventricular assist devices, there remains a pressing need for improved device performance and patient outcomes, and BrioHealth is committed to addressing this gap.”